Biomaterials as vaccine adjuvants

Area of Science:

• Biomaterials science
• Immunology
• Vaccinology

Background:

• Biomaterials are being explored as adjuvants to improve vaccine efficacy.
• Adjuvant design can broaden vaccine applications to challenging diseases such as AIDS, malaria, and cancer.

Purpose of the Study:

• To review vaccine and adjuvant fundamentals for designing effective biomaterial adjuvants.
• To establish guidelines for biomaterial adjuvant design based on disease targets, antigen formulation, and delivery routes.

Main Methods:

• Review of existing literature on biomaterial adjuvants and their mechanisms.
• Analysis of strategies for antigen delivery to dendritic cells.
• Examination of methods for dendritic cell activation and antigen presentation enhancement.
• Investigation of antigen release mechanisms within dendritic cells.

Main Results:

• Ideal biomaterial adjuvants should deliver antigens to dendritic cells, activate them for improved antigen presentation, and ensure appropriate antigen release.
• Strategies like chemokine/cytokine release, antibody targeting, and particle size selection facilitate antigen delivery.
• Biomaterials can activate innate immunity, and specific ligands enhance this effect.
• pH-sensitive release and engineered endosomal release are key for antigen release control.

Conclusions:

• There is a significant opportunity for rational design of advanced biomaterial adjuvants.
• Improved biomaterial adjuvants can substantially expand and enhance vaccine functionality.
• This approach holds promise for developing next-generation vaccines against various diseases.